Objective-Telmisartan, an angiotensin type I receptor blocker (ARB), protects against the progression of atherosclerosis.
T he renin-angiotensin system regulates electrolyte balance, body fluid volume and blood pressure. 1 The renin-angiotensin system also plays an important role in the progression of athersoclerosis. 2 In fact, inhibition of the renin-angiotensin system by either angiotensin-converting enzyme inhibitors or angiotensin type I receptor blockers (ARBs) reduced atherosclerotic lesion formation in experimental studies using various models of atherosclerosis. [3] [4] [5] [6] [7] However, it is possible that the effects of each individual ARB on cardiovascular disease are variable, because there is a difference in pharmacological futures of each ARB, such as liposolubility, potency, stability, and other selective properties.
Macrophages are present in all stages of atherosclerosis and are considered to be fundamental to atherogenesis and the behavior of established plaques. 8 Macrophages take up chemically modified low-density lipoprotein (LDL) through scav-enger receptor pathways and transform into foam cells in vitro. 9 In turn, foam cells produce various bioactive molecules, such as chemokines, cytokines, and growth factors, all of which play important roles in the development and progression of atherosclerosis. 8 On the other hand, several in vivo studies have reported that macrophages and macrophage-derived foam cells proliferate in atherosclerotic lesions. 10 -12 We have shown, 13, 14 as have other groups, 15, 16 that oxidized LDL (Ox-LDL) enhances macrophage proliferation and survival in vitro. Therefore, it is possible that macrophage proliferation may promote the progression of atherosclerosis.
Telmisartan, an ARB, has also been identified as a ligand for peroxisome proliferator-activated receptor-␥ (PPAR␥). 17, 18 PPAR␥ is a transcription factor belonging to the nuclear receptor superfamily that heterodimerizes with the retinoid X receptor and binds to PPAR response elements in target gene promoters. 19 PPAR␥ has many antiatherogenic effects in macrophages, endothelial cells, and smooth muscle cells. 20 Furthermore, PPAR␥ agonists inhibit the development of atherosclerosis in various mouse models of atherosclerosis. 21, 22 Thus, PPAR␥ activation by telmisartan is beneficial for suppressing atherosclerosis. Indeed, telmisartan suppresses the progression of atherosclerosis in apolipoprotein E-deficient (apoE Ϫ/Ϫ ) mice. 23, 24 However, the role of PPAR␥ activation in the protective effects of telmisartan against the progression of atherosclerosis is poorly understood.
Therefore, the aim of the present study was to clarify whether the antiatherogenic effects of telmisartan are mediated by the activation of PPAR␥ in macrophages. We found that telmisartan activated PPAR␥, suppressed tumor necrosis factor-␣ (TNF␣) and monocyte chemoattractant protein-1 (MCP-1) expression, and inhibited Ox-LDL-induced cell proliferation by activating PPAR␥ in macrophages. Telmisartan also activated PPAR␥ in the aorta of apoE Ϫ/Ϫ mice and suppressed the progression of atherosclerosis.
Methods

Cell Culture
The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Kumamoto University, Japan. Peritoneal macrophages were collected from anesthetized male C3H/He mice (body weight, 25 to 30 g) by peritoneal lavage with 8 mL of phosphate-buffered saline (PBS), centrifuged at 200g for 5 minutes, resuspended in medium A (RPMI 1640 medium [Nissui Seiyaku, Tokyo, Japan] supplemented with 10% fetal calf serum [Invitrogen], 0.1 mg/mL streptomycin, and 100 U/mL penicillin), and incubated in tissue culture plates for 90 minutes. 25, 26 More than 98% of the adherent cells were considered to be macrophages, based on 4 criteria, as previously described. 27, 28 RAW264.7 cells were cultured in medium A in tissue culture plates, as previously described, 29 and were used at passages 4 to 8.
Lipoprotein Preparation
Human LDL (dϭ1.019 to 1.063 g/mL) was isolated by ultracentrifugation from plasma samples obtained from consenting normolipidemic subjects after an overnight fast. 26, 30 LDL was dialyzed against 0.15 mol/L NaCl and 1 mmol/L ethylenediaminetetraacetic acid (EDTA), pH 7.4. Ox-LDL was prepared by incubating LDL with 5 mol/L CuSO 4 for 20 hours at 37°C followed by the addition of 1 mmol/L EDTA and cooling. 26, 30 The protein concentration was determined using a BCA protein assay reagent (Pierce Chemical Co, Rockford, IL). The endotoxin level of Ox-LDL was Ͻ1 pg/g protein and was measured using a Toxicolor system (Seikagaku Corp, Tokyo, Japan). 26, 30 Animals ApoE Ϫ/Ϫ mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and were maintained on the C57BL/6 background strain. Mice were housed at the Animal Resource Facility at Kumamoto University under specific pathogen-free conditions and were given free access to food and water. All animal procedures were approved by the Animal Research Committee at Kumamoto University, and all procedures conformed to the Guide for the Care and Use of Laboratory Animals issued by the Institute of Laboratory Animal Resources. The mice were given a normal rodent chow diet developed for mice (CLEA, Tokyo, Japan). Twenty male mice of 6 weeks of age were treated orally with telmisartan (3 mg/kg) or a placebo (control). After 10 weeks of treatment, they were euthanized. Cross-sectional lesions of the aortic sinus were used for real-time reverse transcription-polymerase chain reaction (RT-PCR) assays, and the PPAR␥ transcription activity assay was performed as described below. The whole aorta or 6-m-thick frozen sections of the aortic sinus obtained from apoE Ϫ/Ϫ mice were stained with Oil Red O as previously described. 26, 30 Digital microphotographs of the aortic sinus were analyzed for lesion size in specific regions by measuring the stained surface area using ImageJ software (National Institutes of Health, Bethesda, MD). Blood pressure was determined at the indicated times by the tail-cuff method using a photoelectric tail-cuff detection system (model BP-98A, Softron, Tokyo, Japan). Plasma total cholesterol, triglyceride, and high-density lipoprotein cholesterol concentrations were measured at Skylight Biotech Inc (Akita, Japan). 26, 30 Immunohistochemistry CD11b (Mac-1) and proliferating cell nuclear antigen (PCNA) expression was visualized on frozen aortic sinus sections by immunohistochemistry. After equilibration in PBS, 6-m-thick frozen sections of the aortic sinus were blocked in 3% normal goat serum/2.5% Triton X-100 (Nacalai Tesque, Kyoto, Japan)/PBS for 2 hours at room temperature. Sections were then incubated overnight at 4°C with the primary antibodies anti-PCNA and anti-CD11b (Mac-1) at a 1/100 dilution in blocking solution. After 6 washes with PBS, the sections were incubated with fluorescent-conjugated secondary antibodies Alexa Fluor 546 and Alexa Fluor 488 (Molecular Probes, Eugene, OR) in blocking solution for 2 hours at room temperature. The sections were then counterstained with 4Ј,6diamidino-2-phenylindole solution. After rinsing with PBS, the sections were mounted with Fluoromount (Diagnostic BioSystems, Pleasanton, CA) and examined under a fluorescent microscope (Olympus, Tokyo, Japan). Immunohistochemical analyses were performed on 6 nonconsecutive sections of the aortic sinus obtained from 5 animals per group. 31
Full-Length PPAR␥ Luciferase Assay System
The reporter plasmid (AOX) 3 -luc, containing 3 copies of an upstream activating sequence for the PPAR response element of acyl-coenzyme A oxidase, and the PPAR␥2 expression plasmid (pCMX-PPAR␥2) containing the mouse PPAR␥2 gene, are described elsewhere. 32 To measure PPAR␥ activity, RAW264.7 cells (2ϫ10 6 cells/well) were transfected with (AOX) 3 -luc and pCMX-PPAR␥2 using Lipofectamine 2000 (Invitrogen). Cells were also cotransfected with a Renilla luciferase plasmid (pRL-SV40, Promega) as an internal control. 32 The luciferase assay was performed as described in the supplemental material, available online at http://atvb.ahajournals.org.
GAL4 Chimera Assay for PPAR␣ and PPAR␥
The fusion protein expression vectors pM-PPAR␣ and pM-PPAR␥, containing residues 1 to 147 of the GAL4 DNA-binding domain and residues 167 to 467 of the human PPAR␣ ligand-binding domain, or 204 to 505 of the human PPAR␥ ligand-binding domain, are described elsewhere. 32 The reporter plasmid p4xUASg-tk-luc, containing 4 copies of a 17-mer upstream activating sequence for the GAL4 DNA-binding domain, is also described elsewhere. 32 To measure PPAR␣ or PPAR␥ ligand-binding activity, RAW264.7 cells (2ϫ10 6 cells/well) were transfected with p4xUASg-tk-luc and pM-PPAR␣ or pM-PPAR␥, and luciferase assays were performed as described in the supplemental material.
Materials, luciferase assays, assessment of PPAR␥ transcription activity, small interfering RNA (siRNA) transfection, [ 3 H]thymidine incorporation and cell-counting assays, Western blot analysis, reverse transcription and quantitative RT-PCR, and statistical analysis are described in the supplemental material.
Results
Telmisartan Activates PPAR␥ in Macrophages
First, we investigated the effect of telmisartan on PPAR␥ activation in RAW264.7 macrophages using a full-length PPAR␥ luciferase assay system. Telmisartan increased lu-ciferase activity in a dose-dependent manner ( Figure 1A ). We next examined the effects of telmisartan on luciferase activity using the GAL4 chimera assay of PPAR␥. Telmisartan also increased luciferase activity in a dose-dependent manner in this system ( Figure 1B ). Five mol/L telmisartan increased luciferase activity by 3.8-fold in mouse peritoneal macrophages (PϽ0.01 versus control cells). On the other hand, 10 mol/L losartan, valsartan, and olmesartan did not increase luciferase activity, and the increase in luciferase activity elicited by 10 mol/L pioglitazone was approximately 2.7-fold higher than that at the same concentration of telmisartan ( Figure 1C ). Interestingly, telmisartan at Ն10 mol/L increased luciferase activity using GAL4 chimera assay of PPAR␣ in macrophages ( Figure 1D ).
Telmisartan Induces PPAR␥-Responsive Gene Transcription in Macrophages
We next examined whether telmisartan increased the expression of PPAR␥-responsive genes, including CD36, ATPbinding cassette transporter A1 (ABCA1), and ABCG1, and induced the activation of liver X receptor, a member of the nuclear receptor family of transcription factors that also regulates the gene expression of ABCA1 and ABCG1. 33 Ten mol/L telmisartan increased the mRNA expression of CD36, ABCA1 and ABCG1 (Figure 2A to 2C) and increased LXR activity ( Figure 2D ) in mouse peritoneal macrophages. Treatment with PPAR␥ siRNA decreased the expression of PPAR␥ by 71% in macrophages ( Figure 2E ). Compared with treatment with control siRNA, the telmisartan-induced increases in mRNA expression of ABCA1 and ABCG1 were suppressed by treatment with PPAR␥ siRNA ( Figure 2F ).
Telmisartan Suppresses Lipopolysaccharide-Induced MCP-1 and TNF␣ Production by Activating PPAR␥
It is well known that inflammatory cytokines, including MCP-1 and TNF␣, are involved in the progression of athero-sclerosis. Therefore, we examined the effects of telmisartan on lipopolysaccharide (LPS)-induced mRNA expression of MCP-1 and TNF␣ in macrophages. Telmisartan suppressed LPS-induced mRNA expression of MCP-1 and TNF␣, whereas losartan, olmesartan, and valsartan did not ( Figure  3A and 3B) . Compared with treatment with control siRNA, the telmisartan-induced suppression of MCP-1 and TNF␣ mRNA expression was restored by treatment with PPAR␥ siRNA (Figure 3C and 3D ). Telmisartan also suppressed LPS-induced nuclear factor-B (NF-B) activation, and this effect was restored by PPAR␥ siRNA ( Figure 3E ).
Telmisartan Suppresses Ox-LDL-Induced Macrophage Proliferation
We next examined the effects of ARBs on Ox-LDL-induced macrophage proliferation. Twenty g/mL of Ox-LDL increased [ 3 H]thymidine incorporation into macrophages, as previously reported, 13, 14, 25, 26 and pretreatment with telmisartan suppressed Ox-LDL-induced [ 3 H]thymidine incorporation in a dose-dependent manner ( Figure 4A ). However, losartan, valsartan, and olmesartan had no such effects ( Figure 4A ). Moreover, treatment with siRNA for PPAR␥ restored the telmisartan-mediated suppression of macrophage proliferation ( Figure 4B ).
Telmisartan Suppresses the Progression of Atherosclerosis in ApoE ؊/؊ Mice by Activating PPAR␥
Treatment with telmisartan did not affect body weight, systolic blood pressure, diastolic blood pressure, serum total cholesterol, triglyceride, or high-density lipoprotein cholesterol levels in apoE Ϫ/Ϫ mice ( Supplemental Table) . However, telmisartan decreased the size of atherosclerotic lesions in the aorta, as determined by Oil Red O staining ( Figure 5A to 5C). Telmisartan increased transcriptional activity of PPAR␥ in the aorta ( Figure 5D ). Moreover, telmisartan suppressed MCP-1 mRNA expression in the aortic sinus of apoE Ϫ/Ϫ mice ( Figure 5E ) and increased mRNA expression of ABCA1 and ABCG1 ( Figure 5F ). Finally, we investigated the effects of telmisartan on macrophage proliferation in atherosclerotic lesions in apoE Ϫ/Ϫ mice. PCNA-positive and CD11b-positive cells were detected in the atherosclerotic lesion of apoE Ϫ/Ϫ mice (Figure 6A , top) and the number of CD11b-positive cells was decreased in the atherosclerotic lesions in telmisartan-treated mice, as compared with control mice (Figure 6A, bottom, and 6B) . Moreover, the ratio of PCNApositive cells to all CD11b-positive cells was decreased in the atherosclerotic lesions of telmisartan-treated mice ( Figure 6A and 6C).
Discussion
Angiotensin II activates the AT 1 receptor to promote vasoconstriction, oxidative stress, inflammation, and atherosclerosis. 34 -37 Thus, it is reasonable that blockade of the AT 1 receptor prevents the formation of atherosclerotic lesions. In fact, ARBs were reported to suppress inflammation, reduce neointimal formation and decrease smooth muscle cell proliferation. 38 -43 Because atherosclerosis is thought to be a chronic inflammatory disease, it is possible that treatment with ARBs prevents the progression of atherosclerosis. On the other hand, telmisartan is capable of not only blocking the AT 1 receptor signal but also activating PPAR␥. Because the activation of PPAR␥ also induces antiatherosclerotic effects, telmisartan may have an additive effect for the prevention of atherosclerotic lesion formation.
In the present study, we showed that telmisartan at concentrations Ն1 mmol/L activates PPAR␥ in macrophages, whereas the plasma concentration of telmisartan in hypertensive patients was reported to be 0.54 mol/L. 44 In fact, we revealed in the present study that PPAR␥ activity was increased in the aorta of telmisartan-treated apoE Ϫ/Ϫ mice. Therefore, it is possible that, in clinical use, telmisartan activates PPAR␥ in macrophages present in atherosclerotic lesions. Interestingly, a novel finding is that telmisartan slightly but significantly activated PPAR␣ in macrophages. Because PPAR␣ induces several antiinflammatory effects and suppresses the progression of atherosclerosis, the telmisartan-mediated antiatherogenic effects may be mediated by activation of both PPAR␣ and PPAR␥. Additional studies are needed to clarify the role of PPAR␣ on the antiatherogenic effects of telmisartan.
In the present study, we demonstrated that telmisartan increased the expression of CD36, ABCA1 and ABCG1, 3 PPAR␥-responsive genes, and the activation of LXR, a transcription factors that regulates ABCA1 and ABCG1 gene transcription, in macrophages. We also demonstrated that telmisartan increased the mRNA expression of ABCA1 and ABCG1 in atherosclerotic lesions of apoE Ϫ/Ϫ mice. This finding is supported by a previous report that telmisartan, as well as losartan metabolite, activates PPAR␥ target genes, including CD36, in monocytes 45 and that telmisartan increases cholesterol efflux via PPAR␥-dependent ABCA1 and ABCG1 expression in macrophages. 46 Thus, telmisartan may mediate cholesterol efflux by activating PPAR␥, representing one of the protective effects of telmisartan on the progression of atherosclerosis. On the other hand, we revealed that telmisartan suppressed the expression of the inflammatory and atherogenic molecules MCP-1 and TNF␣ and the activation of NF-B, a transcriptional factor that regulates of MCP-1 and TNF␣, by activating PPAR␥ in macrophages.
Our in vivo study also demonstrated that telmisartan suppressed the mRNA expression of MCP-1 and TNF␣ in the aorta of apoE Ϫ/Ϫ mice. This finding is supported by a previous report that telmisartan inhibits the transcriptional activation of early growth response gene-1 and NF-B, 2 proinflammatory transcription factors, in macrophages and in atherosclerotic lesions of apoE Ϫ/Ϫ mice. 24 In addition to these findings, our novel findings indicated that the number of macrophages in atherosclerotic lesions decreased in telmisartan-treated mice. Thus, telmisartan may suppress the expression of atherogenic molecules, such as TNF␣ and MCP-1, by activating PPAR␥, and subsequently, it may suppress the recruitment of monocytes into the atherosclerotic lesions.
It has been reported that macrophages and macrophage-derived foam cells proliferate in atherosclerotic lesions in the rabbit aorta 11, 12 and in the coronary artery of humans. 10 Our novel findings also revealed that 28.3% of the macrophages in atherosclerotic lesions of apoE Ϫ/Ϫ mice were proliferative. Because macrophages are capable of expressing proatherogenic molecules, the increase in the number of macrophages by its proliferation may be involved in the progression of atherosclerosis. We revealed that telmisartan reduced the number of proliferative macrophages in these lesions and suppressed Ox-LDL-induced macrophage proliferation via PPAR␥ activation. Thus, the suppression of macrophage proliferation may represent one of the mechanisms underly- ing the antiatherogenic effects of telmisartan in apoE Ϫ/Ϫ mice. It has been reported that the activator of PPAR␥ induces macrophage apoptosis. 47 Thus, telmisartan may not only inhibit the MCP-1 expression and macrophage proliferation but also induce macrophage apoptosis, thereby decreasing the number of macrophages in atherosclerotic lesion. On the other hand, Arai et al reported that Ox-LDL induced AIM (apoptosis inhibitor expressed by macrophages), which can protect macrophage apoptosis, and that early atherosclerotic lesions in AIM-deficient (AIM Ϫ/Ϫ ), LDL receptor-deficient double knockout mice are dramatically reduced compared with AIM ϩ/ϩ LDL receptor Ϫ/Ϫ controls. 48 Thus, telmisartan may inhibit the expression of AIM, thereby inducing macrophage apoptosis. Additional studies are needed to clarify the involvement of macrophage apoptosis in telmisartanmediated antiatherosclerotic effects.
In the present study, we did not observe a significant decrease in blood pressure by telmisartan. A significant decrease in systolic blood pressure by telmisartan with concentration between 1 and 5 mg/kg per day was not observed in mice or rats with normal blood pressure in several studies. 49 -51 Because the dose of telmisartan in our present study was close to that of these previous studies and because the apoE Ϫ/Ϫ mice we used presented normal blood pressure, telmisartan might not have affected blood pressure.
We have previously reported that nifedipine, which is an L-type calcium channel blocker, activates PPAR␥ by downregulating serine phosphorylation of PPAR␥ in macrophages. 32 Moreover, we have reported that nifedipine, similar to telmisartan, suppressed MCP-1 expression and induced ABCA1 expression via PPAR␥ activation. 32 However, there is no evidence whether any differences exist in the effects on the phenotypes of arteriosclerosis between telmisartan and nifedipine. It has been reported that the molecular mechanism of PPAR␥ activation seems to differ between telmisartan and thiazolidinediones. 52, 53 Moreover, although PPAR␥ is the target of both telmisartan and pioglitazone, the profiles of gene expression in 3T3-L1 adipocytes treated with telmisartan are different from those of pioglitazone. 52 Because the mechanism of PPAR␥ activation was also different between nifedipine and telmisartan, antiatherosclerotic effects may be partially different between nifedipine and telmisartan, and an additive effect for the prevention of atherosclerosis may be observed by the combination therapy with these compounds in hypertensive patients. Additional studies are needed to clarify whether additive effects by nifedipine and telmisartan could exist in the antiatherosclerotic action.
In conclusion, we have demonstrated that telmisartan activated PPAR␥ and subsequently exerted antiatherogenic effects in macrophages. Moreover, telmisartan suppressed the progression of atherosclerosis in apoE Ϫ/Ϫ mice by decreasing the number of macrophages in atherosclerotic lesions. Collectively, these results could explain, at least in part, the effectiveness of telmisartan in hypertensive patients and in patients with diabetes and hyperlipidemia who are at high risk for atherosclerotic vascular diseases.
